PARIS--(BUSINESS WIRE)--Regulatory News:
Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the initiation of coverage of its stock by the investment bank Bryan, Garnier & Co with a target price of €2.6.
